These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 22577920)

  • 21. [Management of bradykinin-mediated angioedema].
    Floccard B; Crozon J; Rimmelé T; Vulliez A; Coppere B; Chamouard V; Boccon-Gibod I; Bouillet L; Allaouchiche B
    Ann Fr Anesth Reanim; 2011; 30(7-8):578-88. PubMed ID: 21454034
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Treatment of drugs-associated non-hereditary angioedema mediated by bradykinin].
    Muller Y; Harr T
    Rev Med Suisse; 2016 Jan; 12(500):11-2. PubMed ID: 26946694
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Off-Label Use of Agents for Management of Serious or Life-threatening Angiotensin Converting Enzyme Inhibitor-Induced Angioedema.
    Culley CM; DiBridge JN; Wilson GL
    Ann Pharmacother; 2016 Jan; 50(1):47-59. PubMed ID: 26416949
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful long-term treatment with the bradykinin B2 receptor antagonist icatibant in a patient with hereditary angioedema.
    Greve J; Hoffmann TK; Schuler P; Lang S; Chaker A; Bas M
    Int J Dermatol; 2011 Oct; 50(10):1294-5. PubMed ID: 21950301
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Acquired angioedema due to C1-inhibitor deficiency: CREAK recommendations for diagnosis and treatment].
    Gobert D; Bouillet L; Armengol G; Coppo P; Defendi F; Du-Thanh A; Hardy G; Javaud N; Jeandel PY; Launay D; Panayotopoulos V; Pelletier F; Boccon-Gibod I; Fain O
    Rev Med Interne; 2020 Dec; 41(12):838-842. PubMed ID: 32753245
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Allergy-immunology. New therapies for acute attacks in hereditary angioedema].
    Leimgruber A
    Rev Med Suisse; 2011 Jan; 7(278):103-5. PubMed ID: 21400938
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Successful treatment of ACE inhibitor-induced angioedema with icatibant, a bradykinin B2 receptor antagonist.
    Pucar PA; O'Sullivan M; Goudie A; Marr T; Brusch A
    Med J Aust; 2015 Jun; 202(11):596-7. PubMed ID: 26068694
    [No Abstract]   [Full Text] [Related]  

  • 28. Real-life experience with long-term prophylactic C1 inhibitor concentrate treatment of patients with hereditary angioedema: Effectiveness and cost.
    Rasmussen ER; Aagaard L; Bygum A
    Ann Allergy Asthma Immunol; 2016 May; 116(5):476-7. PubMed ID: 27017563
    [No Abstract]   [Full Text] [Related]  

  • 29. Pediatricians diagnosed few patients with childhood-presented hereditary angioedema: Icatibant Outcome Survey findings.
    Grumach AS; Longhurst HJ; Aberer W; Bouillet L; Caballero T; Bygum A; Zanichelli A; Botha J; Andresen I; Maurer M;
    J Allergy Clin Immunol Pract; 2019 Mar; 7(3):1078-1080. PubMed ID: 30170163
    [No Abstract]   [Full Text] [Related]  

  • 30. Therapeutic potential of icatibant (HOE-140, JE-049).
    Cruden NL; Newby DE
    Expert Opin Pharmacother; 2008 Sep; 9(13):2383-90. PubMed ID: 18710362
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of icatibant-the B2 bradykinin receptor antagonist-in life-threatening laryngeal angioedema in the ED.
    Bartal C; Zeldetz V; Stavi V; Barski L
    Am J Emerg Med; 2015 Mar; 33(3):479.e1-3. PubMed ID: 25241359
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Repeat treatment with icatibant for multiple hereditary angioedema attacks: FAST-2 open-label study.
    Baş M; Greve J; Hoffmann TK; Reshef A; Aberer W; Maurer M; Kivity S; Farkas H; Floccard B; Arcoleo F; Martin L; Sitkauskiene B; Bouillet L; Schmid-Grendelmeier P; Li H; Zanichelli A
    Allergy; 2013 Nov; 68(11):1452-9. PubMed ID: 24111645
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic management of hereditary angioedema due to C1 inhibitor deficiency.
    Zanichelli A; Mansi M; Periti G; Cicardi M
    Expert Rev Clin Immunol; 2013 May; 9(5):477-88. PubMed ID: 23634741
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment with icatibant in the management of drug induced angioedema.
    Bertazzoni G; Bresciani E; Cipollone L; Fante E; Galandrini R
    Eur Rev Med Pharmacol Sci; 2015 Jan; 19(1):149-53. PubMed ID: 25635988
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factors associated with hospital admission in hereditary angioedema attacks: a multicenter prospective study.
    Javaud N; Gompel A; Bouillet L; Boccon-Gibod I; Cantin D; Smaiti N; Carpentier F; Boubaya M; Launay D; Adnet F; Fain O
    Ann Allergy Asthma Immunol; 2015 Jun; 114(6):499-503. PubMed ID: 25935434
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Triggers and Prodromal Symptoms of Angioedema Attacks in Patients With Hereditary Angioedema.
    Caballero T; Maurer M; Longhurst HJ; Aberer W; Bouillet L; Fabien V;
    J Investig Allergol Clin Immunol; 2016; 26(6):383-386. PubMed ID: 27996949
    [No Abstract]   [Full Text] [Related]  

  • 37. The Angiotensin-Converting-Enzyme-Induced Angioedema.
    Bas M
    Immunol Allergy Clin North Am; 2017 Feb; 37(1):183-200. PubMed ID: 27886906
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successful treatment of hereditary angioedema with bradykinin B2-receptor antagonist icatibant.
    Krause K; Metz M; Zuberbier T; Maurer M; Magerl M
    J Dtsch Dermatol Ges; 2010 Apr; 8(4):272-4. PubMed ID: 19758369
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and biological response to rituximab treatment in 3 patients with acquired C1-inhibitor deficiency.
    Busse PJ; Gernez Y
    Ann Allergy Asthma Immunol; 2017 Oct; 119(4):380-382. PubMed ID: 28866304
    [No Abstract]   [Full Text] [Related]  

  • 40. Hereditary angioedema therapies in the United States: movement toward an international treatment consensus.
    Riedl M
    Clin Ther; 2012 Mar; 34(3):623-30. PubMed ID: 22386830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.